. 2015 Oct 22;119(12):1411–1420. doi: 10.1152/japplphysiol.00729.2015

Table 3.

Hemodynamic variables at each experimental phase

	Condition
	Thermoneutral		ΔT_es = 0.4°C	ΔT_es = 0.8°C
	Upright	Supine	Supine	Supine	Upright	Upright exercise	Supine exercise
SBP, mmHg
Young	105 ± 3	103 ± 3	104 ± 3	108 ± 3	100 ± 2	128 ± 4	125 ± 4
Older placebo	116 ± 4^*	114 ± 4^*	111 ± 3^*	115 ± 4^*	105 ± 4	144 ± 7^*	142 ± 7^*
Older sapropterin	115 ± 3	112 ± 3	107 ± 3	108 ± 3	105 ± 5	143 ± 8	142 ± 6
DBP, mmHg
Young	66 ± 2	62 ± 2	59 ± 2	57 ± 2	54 ± 2	54 ± 2	55 ± 2
Older placebo	65 ± 2	65 ± 2	63 ± 2	61 ± 2^*	54 ± 2	63 ± 3^*	66 ± 2^*
Older sapropterin	65 ± 2	64 ± 2	61 ± 2	60 ± 1	56 ± 2	62 ± 3	65 ± 2
PP, mmHg
Young	39 ± 2	41 ± 2	45 ± 3	52 ± 4	47 ± 2	75 ± 4	71 ± 5
Older placebo	50 ± 4^*	50 ± 4^*	49 ± 4	54 ± 5	50 ± 4	81 ± 8	75 ± 6
Older sapropterin	50 ± 4	48 ± 3	47 ± 3	48 ± 4	50 ± 4	81 ± 9	77 ± 6
%HRR, beats/min
Young	8 ± 2	—	6 ± 6	18 ± 1	30 ± 3	46 ± 3	45 ± 3
Older placebo	8 ± 2	—	11 ± 2	16 ± 2	26 ± 3	54 ± 6	50 ± 5
Older sapropterin	8 ± 2	—	10 ± 1	15 ± 2	24 ± 3	53 ± 5	54 ± 5
CI, l/m²
Young	4.0 ± 0.1	4.0 ± 0.1	4.7 ± 0.2	5.4 ± 0.2	4.9 ± 0.2	7.1 ± 0.2	7.1 ± 0.3
Older placebo	3.0 ± 0.2^*	3.0 ± 0.2^*	3.7 ± 0.2^*	3.7 ± 0.2^*	3.6 ± 0.2^*	6.5 ± 0.3^*	6.2 ± 0.3^*
Older sapropterin	3.1 ± 0.2	3.0 ± 0.1	3.6 ± 0.2	3.9 ± 0.2	3.8 ± 0.2	6.3 ± 0.2	6.6 ± 0.2
TPR, mmHg·l⁻¹·min
Young	11 ± 0.6	11 ± 0.4	9 ± 0.4	8 ± 0.3	8 ± 0.2	6 ± 0.2	6 ± 0.2
Older placebo	15 ± 1.4	15 ± 1.4	12 ± 0.9	12 ± 0.9	11 ± 0.7	8 ± 0.5	8 ± 0.5
Older sapropterin	14 ± 1.1	15 ± 1.1	12 ± 0.9	11 ± 1.0	11 ± 0.9	8 ± 0.4	7 ± 0.4
SVC, mmHg·l⁻¹·min
Young	92 ± 5	97 ± 5	115 ± 6	133 ± 6	129 ± 5	163 ± 5	165 ± 6
Older placebo	73 ± 6^*	71 ± 6^*	88 ± 6^*	91 ± 6^*	96 ± 6^*	134 ± 7^*	128 ± 7^*
Older sapropterin	73 ± 5	73 ± 5	91 ± 6	99 ± 8	100 ± 8	135 ± 6	138 ± 6

Values are means ± SE. PP, pulse pressure; HRR, heart rate reserve; CI, cardiac index; TPR, total peripheral resistance; SVC, systemic vascular conductance.

P < 0.05, older: placebo vs. young.